Morgan Stanley Downgrades Novo Nordisk (NYSE: NVO) As Semaglutide Patent Cliff Threatens Terminal Value

Morgan Stanley Downgrades Novo Nordisk (NYSE: NVO) As Semaglutide Patent Cliff Threatens Terminal Value

Novo Nordisk A/S (NYSE: NVO) received a downgrade to Underweight from Morgan Stanley on September 11, 2026, sending shares down an additional 2% following the call. Semaglutide, the underlying molecule powering both Wegovy and Ozempic, currently accounts for roughly 75% of Novo Nordisk’s 2026 revenue, making it the company’s single most critical commercial asset. Morgan […]

Novo Nordisk Stock Slides Nearly 8% in New York After $23 Billion Pipeline Plan Disappoints Investors

Novo Nordisk stock fell nearly 8% in New York trading on Monday after the drugmaker's Capital Markets Day failed to convince investors that its pipeline can fully replace the extraordinary growth generated by Wegovy and Ozempic as semaglutide approaches the end of its patent-protected life. The NYSE-listed ADR, NVO, was down 7.86% at around 18:15 GMT on September 21, according to TradingKey, after the selloff had already swept through Copenhagen…

Novo Nordisk A/S (NOVO) Stock: Wegovy Lead Meets Long-Term Challenges

TLDR Novo stock drops 7.65% as pipeline setbacks deepen long-term growth concerns. Wegovy still supports sales, but semaglutide patent expiries approach next decade. LSEG projects Zepbound sales will exceed Wegovy by more than $7 billion in 2026. Novo may pursue more acquisitions and licensing deals to strengthen its pipeline. Zenagamtide gains attention as CagriSema setbacks [...]

Novo Nordisk Stock Slides 8% as $23 Billion Pipeline Goal Leaves a 2032 Gap

New York, September 21, 2026, 13:16 (EDT) Novo’s ADRs traded at $39.705, down 8.18%, at 13:02 EDT.Management targets more than DKK 150 billion in pipeline sales by 2035.A U.S. CagriSema decision is expected during the fourth quarter. Novo Nordisk A/S (NYSE:NVO; CPH:NOVO-B) fell 8.18% to $39.705 by 13:02 EDT. Volume reached 34.2 million ADRs after…